Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi Sells 7,886 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi sold 7,886 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total transaction of $51,968.74. Following the sale, the chief operating officer now directly owns 233,390 shares of the company’s stock, valued at $1,538,040.10. This represents a 3.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Azmi Nabulsi also recently made the following trade(s):

• On Thursday, December 19th, Azmi Nabulsi sold 1,118 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total transaction of $8,944.00.

Phathom Pharmaceuticals Trading Up 2.6 %

PHAT stock opened at $7.17 on Friday. The company has a 50 day moving average of $8.08 and a two-hundred day moving average of $12.53. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.57) by $0.25. The firm had revenue of $16.35 million for the quarter, compared to analyst estimates of $12.54 million. During the same period in the previous year, the business posted ($0.76) EPS. Equities research analysts expect that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Large investors have recently made changes to their positions in the company. State Street Corp lifted its stake in Phathom Pharmaceuticals by 17.5% in the third quarter. State Street Corp now owns 922,788 shares of the company’s stock valued at $16,684,000 after acquiring an additional 137,539 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in Phathom Pharmaceuticals by 25.9% in the third quarter. Eagle Asset Management Inc. now owns 455,196 shares of the company’s stock worth $7,675,000 after purchasing an additional 93,733 shares in the last quarter. FMR LLC increased its position in Phathom Pharmaceuticals by 49,000.7% during the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after buying an additional 1,301,458 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Phathom Pharmaceuticals during the third quarter valued at about $7,952,000. Finally, Jennison Associates LLC lifted its position in shares of Phathom Pharmaceuticals by 112.7% in the third quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock worth $106,064,000 after buying an additional 3,108,810 shares during the last quarter. Institutional investors own 99.01% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on PHAT shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.